Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series

Abstract

Objectives Combination biological therapies are being increasingly considered for patients with multiple comorbidities requiring biologics. There is limited data available on this approach and concerns remain about the possible risk of adverse events, particularly infection. Methods We present three patients on dual biologics for rheumatic disease and asthma. The biologic combinations used include etanercept and mepolizumab, infliximab and omalizumab and etanercept and omalizumab. The time on combination biologic therapies ranges from 24 to 36 months. Patient were monitored for any serious adverse events. Results All three patients were able to tolerate combined biologic therapies, with no serious adverse events. All three patients gained improvement in their rheumatic and asthma disease control, with reduction in disease activity scores and reduction in steroid usage. Conclusion The decision to start dual biologic therapy should be carefully considered on a case-by case basis. The number of patients who are on combination biological therapy is small and data is sparse. Real world data is needed to examine the long-term benefits and risks of different forms of combination biologic therapies. Lay summary What does this mean for patients ? Biological therapies are specific therapies that target particular parts of the immune system. These medications are used in the treatment of autoimmune conditions like rheumatoid arthritis. In rheumatoid arthritis they work by stopping particular chemicals in blood from activating the immune system to attack joints. They are very effective medications which treat inflammatory autoimmune conditions. In some cases, they may be associated with side effects, particularly increased risk of infections. We have written a case series about three people who have inflammatory autoimmune conditions and are receiving two biologics to treat these. All three people have inflammatory arthritis and asthma and are receiving two different biological therapies. They have been receiving these for a period ranging from 24 to 36 months. All three people have been able to tolerate combined biologic therapies with no serious adverse events thus far. They have gained improvement in their arthritis and asthma control, with reduction in disease activity and the use of steroids. Although the number of people receiving more than one biological treatment is small, this study suggests that dual therapy could be used in certain situations. The decision to start dual biologic therapy should be carefully considered on a case-by case basis by the specialists.

Articular manifestations related to anti-interleukin-5 therapies in severe asthma: a case series

“…Nonetheless, expert rheumatologic evaluation and management is essential, as these articular manifestations may have an important functional impact, a potential progression to joint destruction and may require the use of DMARDs. As already reported, dual biologic therapy for treating rheumatic diseases and severe asthma was safe and well tolerated [15,16].…”

Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain

“…Malik et al. presented three patients on dual biologics for rheumatic disease (two RA and other with Crohn´s-associated arthritis) and concomitant asthma, combining mepolizumab or omalizumab with anti-TNF and no SAEs were reported ( 52 ). Yıldırım et al.…”